Market open
Akero Therapeutics/$AKRO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Akero Therapeutics
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
Ticker
$AKRO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
69
ISIN
US00973Y1082
Website
AKRO Metrics
BasicAdvanced
$3B
-
-$3.74
-0.13
-
Price and volume
Market cap
$3B
Beta
-0.13
52-week high
$58.40
52-week low
$17.86
Average daily volume
1.3M
Financial strength
Current ratio
16.804
Quick ratio
16.171
Long term debt to equity
2.727
Total debt to equity
2.727
Interest coverage (TTM)
-63.41%
Management effectiveness
Return on assets (TTM)
-18.52%
Return on equity (TTM)
-27.92%
Valuation
Price to book
2.78
Price to tangible book (TTM)
2.78
Price to free cash flow (TTM)
-10.342
Growth
Earnings per share change (TTM)
16.23%
3-year earnings per share growth (CAGR)
5.35%
What the Analysts think about AKRO
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Akero Therapeutics stock.
AKRO Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AKRO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AKRO News
AllArticlesVideos
Best Biotech Stocks to Buy in 2025
MarketBeat·2 days ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Stockholders to Learn More About the Investigation
Accesswire·4 days ago
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
GlobeNewsWire·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Akero Therapeutics stock?
Akero Therapeutics (AKRO) has a market cap of $3B as of May 15, 2025.
What is the P/E ratio for Akero Therapeutics stock?
The price to earnings (P/E) ratio for Akero Therapeutics (AKRO) stock is 0 as of May 15, 2025.
Does Akero Therapeutics stock pay dividends?
No, Akero Therapeutics (AKRO) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Akero Therapeutics dividend payment date?
Akero Therapeutics (AKRO) stock does not pay dividends to its shareholders.
What is the beta indicator for Akero Therapeutics?
Akero Therapeutics (AKRO) has a beta rating of -0.13. This means that it has an inverse relation to market volatility.